CircleDNA is our in-house developed consumer genetic testing offering, which brings technologically advanced genetic testing to our customers along with comprehensive reports accessible at our customers’ fingertips. It employs whole exome sequencing, a next-generation sequencing method, that can identify up to 90% of the genetic variants associated with cancers and certain other diseases.
Customers have access to over 500 reports across 20 categories covering disease risks, drug response, family planning, diet, common health risks, personal traits and nutrition, among others, which enable early detection of diseases and allow them to take preventive measures and make healthier life choices. Find out more
ColoClear is a non-invasive, stool-based FIT-DNA test for colorectal cancer screening test for detecting early signs of colorectal cancer using at-home sample collection, providing an easy alternative to Colonoscopy. According to clinical studies, the sensitivity of ColoClear is up to 96% in colorectal cancer and 64% in advanced adenoma detection. It is the only cancer screening test approved by the National Medical Products Administration (NMPA). Find out more
- Project Screen: The Covid-19 Initiative
Prenetics launched Project Screen, an initiative for COVID-19 testing approved and adopted by the Hong Kong and United Kingdom government. Prenetics, driven by a duty of responsibility, has now performed more than 6 million PCR laboratory tests globally and has a daily testing capacity of over 40,000 tests.
We are the sole provider of COVID-19 tests to all 20 clubs in the English Premier League, have many blue-chip clientele including Virgin Atlantic and operate 11 labs. Find out more
- Circle HealthPod
Circle HealthPod is a health monitoring system that provides rapid, lab-quality molecular testing for COVID-19 and is being developed for influenza and STDs — anytime, anywhere in 30 minutes. Utilizing technology developed in collaboration with the University of Oxford, Circle HealthPod has received CE-IVD mark, completed a usability study in the U.S. and a clinical validation is in progress with aim to receive EUA from U.S. FDA by early 2022.
Our mission is to leverage science to rapidly detect disease, anytime and anywhere. Find out more